Biliary Tract Cancer<\/b><\/p>\n<\/td>\n<\/tr>\n Presidential Symposium Presentation: <\/b>Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: a randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1)<\/p>\n \nPresidential Symposium II, Oct 25, 5:42-5:54 pm CET, Abstract #LBA8<\/p>\n<\/td>\n<\/tr>\n Endometrial Cancer<\/b><\/p>\n<\/td>\n<\/tr>\n Poster: <\/b>A phase 2 study of ivonescimab (PD1\/VEGF bispecific antibody) for the treatment of endometrial cancer (EC)<\/p>\n \nAbstract #1266P<\/p>\n<\/td>\n<\/tr>\n Esophageal Squamous Cell Carcinoma<\/b><\/p>\n<\/td>\n<\/tr>\n Poster:<\/b> Ivonescimab (AK112) plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma: A phase 2 single-arm study<\/p>\n \nAbstract #2908P<\/p>\n<\/td>\n<\/tr>\n Gastric and GEJ Adenocarcinoma<\/b><\/p>\n<\/td>\n<\/tr>\n Poster:<\/b> AK112 (PD-1\/VEGF bispecific antibody) combined with low-dose radiotherapy and nab-paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma: A prospective, multicenter, phase II study<\/p>\n \nAbstract #2898P<\/p>\n<\/td>\n<\/tr>\n Glioblastoma<\/b><\/p>\n<\/td>\n<\/tr>\n Poster:<\/b> Ivonescimab combined with dose-dense temozolomide in recurrent glioblastoma: Preliminary results of efficacy and safety from a single-arm, phase Ib\/II trial<\/p>\n \nAbstract #706P<\/p>\n<\/td>\n<\/tr>\n Head and Neck Squamous Cell Carcinoma<\/b><\/p>\n<\/td>\n<\/tr>\n Poster:<\/b> Ivonescimab combined with chemotherapy as first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma: A prospective, open-label, single-arm phase II study<\/p>\n \nAbstract #1676eTiP<\/p>\n<\/td>\n<\/tr>\n Pancreatic Cancer<\/b><\/p>\n<\/td>\n<\/tr>\n Poster:<\/b> Neoadjuvant ivonescimab plus gemcitabine\/nab-paclitaxel for borderline resectable pancreatic cancer: A prospective single-arm phase II trial<\/p>\n \nAbstract #3161P<\/p>\n<\/td>\n<\/tr>\n Renal Cell Carcinoma<\/b><\/p>\n<\/td>\n<\/tr>\n Oral Presentation:<\/b> Efficacy and safety of AK112 (Ivonescimab), a PD-1\/VEGF bispecific antibody, as first-line treatment for patients with IMDC favorable-risk advanced renal cell carcinoma (aRCC): Results from a phase Ib\/II study<\/p>\n \nProffered Paper 2 Session: Genitourinary Tumours, Renal and Urothelial; Oct 25, 9:32-9:42 am CET, Abstract #3592O<\/p>\n<\/td>\n<\/tr>\n Thymic Carcinoma<\/b><\/p>\n<\/td>\n<\/tr>\n Rapid Oral Presentation: <\/b>Ivonescimab plus chemotherapy as first-line treatment in recurrent\/metastatic thymic carcinoma: Results from the iTHYM phase II study<\/p>\n \nRapid Oral Session: Non-metastatic NSCLC and Other Thoracic Malignancies; Oct 26, 11:07-11:12 am CET, Abstract #4156RO<\/p>\n<\/td>\n<\/tr>\n Poster: <\/b>Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: Preliminary results from a phase II study with dynamic biomarker exploration<\/p>\n \nAbstract #2020eP<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nIvonescimab is an investigational therapy that is not approved by any regulatory authority in Summit\u2019s license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024.<\/p>\n About Ivonescimab<\/b><\/p>\n \nIvonescimab, known as SMT112 in Summit\u2019s license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit\u2019s license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF.<\/p>\n \nThis design is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Summit believes ivonescimab\u2019s specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al<\/i>, iScience, 2025). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of ivonescimab\u2019s design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al<\/i>, iScience, 2025) increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets.<\/p>\n \nIvonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies globally and over 100,000 patients when considering those treated in a commercial setting in China, as noted by Akeso.<\/p>\n \nThere are currently 17 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, five of which are Summit-sponsored global studies, two of which are studies sponsored by cooperative groups, and 10 of which are being or have been conducted in China by Akeso. Summit began its clinical development of ivonescimab in NSCLC and expanded its sponsored Phase III clinical development program into colorectal cancer (CRC) and urothelial carcinoma (bladder cancer).<\/p>\n About Summit Therapeutics Inc.<\/b><\/p>\n \nSummit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.<\/p>\n \nSummit was founded in 2003 and the company\u2019s shares are listed on the Nasdaq Global Market (symbol “SMMT”). Summit is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.<\/p>\n \nFor more information, please visit https:\/\/www.smmttx.com<\/a> and follow Summit on X @SMMT_TX.<\/p>\n Summit Forward-Looking Statements<\/b><\/p>\n \nAny statements in this press release about the Company\u2019s future expectations, plans and prospects, including but not limited to, statements about the risk that the private placement does not close on the anticipated timeline or at all, including because required regulatory clearances are not obtained or other closing conditions are not satisfied, dilution to existing stockholders, and potential adverse effects on the market price of the Company’s common stock, including from future sales by AstraZeneca, the Company\u2019s broad discretion over the use of proceeds, and the possibility that the proceeds will not be sufficient to fund operations as long as anticipated, AstraZeneca\u2019s ownership and contractual rights, including Third Party acquisition participation, and registration rights, and potential conflicts of interest, the completion of the Private Placement does not depend on the parties entering into a definitive collaboration agreement, the Company’s reliance on AstraZeneca for the supply of AstraZeneca\u2019s products and other contributions to the clinical trials, the clinical and preclinical development of the Company\u2019s product candidates, entry into and actions related to the Company\u2019s partnership with Akeso Inc. and other collaborations, the intended use of the net proceeds from the private placements, the Company’s anticipated spending and cash runway, the therapeutic potential of the Company\u2019s product candidates, the potential commercialization of the Company\u2019s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program (\u201cATM Program\u201d), the expected proceeds and uses thereof, the Company\u2019s estimates regarding stock-based compensation, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company\u2019s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company\u2019s pipeline of drug candidates, including without limitation, through potential acquisitions of, and\/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company\u2019s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a \u201cpositive study\u201d as a clinical study with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company\u2019s views only as of the date of this release and should not be relied upon as representing the Company\u2019s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.<\/p>\n \nSummit Therapeutics and the Summit Therapeutics logo are registered trademarks of Summit Therapeutics Inc. and\/or its affiliates. Copyright 2026, Summit Therapeutics Inc. All Rights Reserved.<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20261022076516\/en\/<\/a><\/span><\/p>\n Summit Therapeutics\u2019 Media & Investor Contacts: \nTracy Jones investors@smmttx.com KEYWORDS:<\/b> Florida Europe Spain United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Research Clinical Trials Biotechnology Other Health Health Pharmaceutical Other Science Science Oncology<\/p>\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/p>\n
\n<\/b>
Nathan LiaBraaten
\n
Senior Director, Investor Relations<\/p>\n
\n
Director, Media & Public Relations<\/p>\n
\n<\/a>
media@smmttx.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20261022076516\/en\/2824724\/3\/2026_SMMT_Logo_%28R%29.jpg\"){kind=logo}
<\/td>\n<\/tr>\n